The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials
1
School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia
2
Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
3
Department of Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, Usmanu Danfodiyo University, PMB 2254 Sokoto, Nigeria
4
Metabolomics and Enzymology Unit, Fundamental and Applied Biology Group, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia
5
School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia
*
Author to whom correspondence should be addressed.
Genes 2018, 9(4), 174; https://doi.org/10.3390/genes9040174
Received: 8 January 2018
/
Revised: 5 March 2018
/
Accepted: 5 March 2018
/
Published: 21 March 2018
(This article belongs to the Section Human Genomics and Genetic Diseases)
MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that post-transcriptionally regulate gene expression by base pairing with mRNA targets. Altered miRNA expression profiles have been observed in several diseases, including neurodegeneration. Multiple studies have reported altered expressions of miRNAs in the brains of individuals with Alzheimer’s disease (AD) as compared to those of healthy elderly adults. Some of the miRNAs found to be dysregulated in AD have been reported to correlate with neuropathological changes, including plaque and tangle accumulation, as well as altered expressions of species that are known to be involved in AD pathology. To examine the potentially pathogenic functions of several dysregulated miRNAs in AD, we review the current literature with a focus on the activities of ten miRNAs in biological pathways involved in AD pathogenesis. Comprehensive understandings of the expression profiles and activities of these miRNAs will illuminate their roles as potential therapeutic targets in AD brain and may lead to the discovery of breakthrough treatment strategies for AD.
View Full-Text
Keywords:
miRNAs; Alzheimer’s disease; BACE1 inhibitors; γ-secretase inhibitors
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Miya Shaik, M.; Tamargo, I.A.; Abubakar, M.B.; Kamal, M.A.; Greig, N.H.; Gan, S.H. The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials. Genes 2018, 9, 174. https://doi.org/10.3390/genes9040174
AMA Style
Miya Shaik M, Tamargo IA, Abubakar MB, Kamal MA, Greig NH, Gan SH. The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials. Genes. 2018; 9(4):174. https://doi.org/10.3390/genes9040174
Chicago/Turabian StyleMiya Shaik, Munvar, Ian A. Tamargo, Murtala B. Abubakar, Mohammad A. Kamal, Nigel H. Greig, and Siew H. Gan. 2018. "The Role of microRNAs in Alzheimer’s Disease and Their Therapeutic Potentials" Genes 9, no. 4: 174. https://doi.org/10.3390/genes9040174
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
